welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Tucson pharmaceutical company sells exclusive option for cancer drug in deal worth up to $190 million
Sucampo unveiled Monday its agreement with Tuscon, Arizona-based Cancer Prevention Pharmaceuticals Inc. for the option to acquire an exclusive license to commercialize for a drug candidate in Phase III clinical trials. The therapy is aimed at treating a genetic condition called Familial Adenomatous Polyposis, or FAP, which can develop into colon cancer if it’s left untreated.
expertly curated content related to this topic
-
Scott K. Kuwada, MDScott K. Kuwada, MD joined The Queen’s...
-
Karen Hurley, PhDI am a licensed clinical psychologist sp...
-
Steven M. Lipkin, MD, PhDDr. Lipkin is a board certified Clinical...
-
Douglas K. Rex, MDDouglas Kevin Rex is an American gastroe...
-
PTSD common in patients with familial adenomatous polyposisPosttraumatic stress disorder is common ...
-
Thetis Pharmaceuticals to Present at the World Orphan Drug Congress on TP-252, an Investigational Drug for Familial ...Thetis Pharmaceuticals LLC (“Thetis”...
-
John Carethers, MD – Video Profilehttps://www.youtube.com/watch?v=Gehwf4DM...